PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 223 filers reported holding PDL BIOPHARMA INC in Q4 2013. The put-call ratio across all filers is 0.28 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $317,000 | +2.6% | 128,338 | -5.8% | 0.00% | 0.0% |
Q1 2017 | $309,000 | -21.4% | 136,247 | -26.6% | 0.00% | 0.0% |
Q4 2016 | $393,000 | +30.6% | 185,610 | +106.3% | 0.00% | 0.0% |
Q3 2016 | $301,000 | -92.6% | 89,982 | -92.2% | 0.00% | -90.9% |
Q4 2015 | $4,071,000 | -96.2% | 1,150,124 | -94.6% | 0.01% | -96.5% |
Q3 2015 | $107,655,000 | -4.5% | 21,402,567 | +22.0% | 0.31% | +6.5% |
Q2 2015 | $112,762,000 | +13.6% | 17,536,793 | +24.3% | 0.29% | +0.3% |
Q1 2015 | $99,283,000 | +48.2% | 14,112,748 | +62.4% | 0.29% | +29.2% |
Q4 2014 | $67,012,000 | +715.4% | 8,691,598 | +690.1% | 0.23% | +606.2% |
Q3 2014 | $8,218,000 | -27.8% | 1,100,109 | -6.4% | 0.03% | -31.9% |
Q2 2014 | $11,379,000 | +33.3% | 1,175,524 | +14.4% | 0.05% | +23.7% |
Q1 2014 | $8,538,000 | -18.6% | 1,027,417 | -17.4% | 0.04% | -25.5% |
Q4 2013 | $10,494,000 | +11.7% | 1,243,372 | +5.5% | 0.05% | 0.0% |
Q3 2013 | $9,394,000 | +6.8% | 1,178,712 | +3.5% | 0.05% | -10.5% |
Q2 2013 | $8,795,000 | – | 1,139,224 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SMH CAPITAL ADVISORS INC | 81,713 | $176,000 | 0.39% |
BRANDES INVESTMENT PARTNERS, LP | 5,465,156 | $11,805,000 | 0.30% |
Crestline Management, LP | 875,000 | $1,890,000 | 0.30% |
West Family Investments, Inc. | 539,450 | $1,165,000 | 0.29% |
WEBER ALAN W | 200,000 | $432,000,000 | 0.19% |
Zebra Capital Management LLC | 73,910 | $160,000 | 0.18% |
RBF Capital, LLC | 569,323 | $1,230,000 | 0.14% |
Leap Investments LP | 69,496 | $150,000 | 0.08% |
Connor, Clark & Lunn Investment Management Ltd. | 4,387,038 | $9,476,000 | 0.06% |
CHICAGO EQUITY PARTNERS LLC | 519,315 | $1,122,000 | 0.05% |